(Q81820052)
Statements
Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors (English)
Gary K Schwartz
Aaron Weitzman
Les Brail
Dinesh P de Alwis
Ann Cleverly
Barbara Barile-Thiem
Vincent Vinciguerra